Clinical Trials

Title

A Phase 1B/2 Pan-Tumor, Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

• Short Title DS7300-203 Daiichi Sankyo
• Category Gynecologic Oncology
• Status Recruiting

Participating Locations

Erlanger

Principal Investigator

Stephen DePasquale, MD

Contact

• Name Erlanger Institute for Clinical Research
• Phone 4237783900
• Email [email protected]

Description

This open-label study will evaluate the efficacy and safety of Ifinatamab Deruxtecan (I-DXd) in participants with recurrent or metastatic solid tumors previously treated with one or more systemic therapies for the selected tumor indication. (IDeate-antumor02).